These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20386384)

  • 1. A rare case of severe myopathy associated with etravirine use.
    Tommasi C; Tempestilli M; Fezza R; Bellagamba R; Nicastri E; D'offizi G; Pucillo LP; Narciso P
    AIDS; 2010 Apr; 24(7):1088-90. PubMed ID: 20386384
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine.
    Carbone A; Bigoloni A; Galli L; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    AIDS; 2013 Oct; 27(16):2661-3. PubMed ID: 24096632
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
    Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
    AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etravirine(Intelence) for HIV infection.
    Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091
    [No Abstract]   [Full Text] [Related]  

  • 5. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
    Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No hepatotoxicity found for etravirine.
    AIDS Patient Care STDS; 2008 Dec; 22(12):1022. PubMed ID: 19097262
    [No Abstract]   [Full Text] [Related]  

  • 7. [Toxic drug-induced proximal myopathy in CDC C3 HIV-infection].
    Weisser M
    Praxis (Bern 1994); 1997 Oct; 86(43):1708-10. PubMed ID: 9432697
    [No Abstract]   [Full Text] [Related]  

  • 8. [Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():1. PubMed ID: 20116620
    [No Abstract]   [Full Text] [Related]  

  • 9. [Muscular complications in HIV infection].
    Authier FJ; Chariot P; Gherardi R
    Arch Anat Cytol Pathol; 1997; 45(2-3):174-8. PubMed ID: 9382610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
    Kakuda TN; Schöller-Gyüre M; Workman C; Arasteh K; Pozniak AL; De Smedt G; Beets G; Peeters M; Vandermeulen K; Woodfall BJ; Hoetelmans RM
    Antivir Ther; 2008; 13(5):655-61. PubMed ID: 18771049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of etravirine.
    Fullerton DS; Watson MJ; Anderson D; Witek J; Martin SC; Mrus JM
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):485-95. PubMed ID: 20950062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
    Parsonage MJ; Wilkins EG; Snowden N; Issa BG; Savage MW
    HIV Med; 2005 Sep; 6(5):341-6. PubMed ID: 16156882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
    Johnson LB; Saravolatz LD
    Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
    Ménard A; Solas C; Mokthari S; Bregigeon S; Drogoul MP; Tamalet C; Lacarelle B; Martin IP
    AIDS; 2009 Apr; 23(7):869-71. PubMed ID: 19363331
    [No Abstract]   [Full Text] [Related]  

  • 20. New drugs: Etravirine, sinecatechins, and desvenlafaxine succinate.
    Hussar DA; Campoli KE
    J Am Pharm Assoc (2003); 2008; 48(3):428-31. PubMed ID: 18595832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.